Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Larsen, Jeremy T., Shanafelt, Tait D., Leis, Jose F., LaPlant, Betsy, Call, Tim, Pettinger, Adam, Hanson, Curtis, Erlichman, Charles, Habermann, Thomas Matthew, Reeder, Craig, Nikcevich, Daniel, Bowen, Deborah, Conte, Michael, Boysen, Justin, Secreto, Charla, Lesnick, Connie, Tschumper, Renee, Jelinek, Diane, Kay, Neil E., Ding, Wei
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507724/
https://ncbi.nlm.nih.gov/pubmed/28402581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24762
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky